Market Research Logo

Global Prostate Cancer Drugs Market 2016-2020

Global Prostate Cancer Drugs Market 2016-2020

About Prostate Cancer Drugs

Prostate cancer is the cancer of prostate gland. According to CDC, it is one of the leading cause of cancer death in men across the races in the US. According to the Urology Care Foundation, globally, one in seven men will be diagnosed with the disease. About one in 35 men die due to prostate cancer. Growth in the prostate can be benign or malignant. Prostate cancer cells spread by breaking away from a prostate tumor. They may travel through blood vessels or lymph vessels and reach other parts of the body. The cells that spread might bind to other tissues, form new tumors, and sometimes damage those tissues as well. When prostate cancer cells spread from their original place to another, the new tumor formed also has the same kind of abnormal cells.

Technavio’s analysts forecast the global prostate cancer drugs market to grow at a CAGR of 9.21% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global prostate cancer drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Prostate Cancer Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Johnson & Johnson
  • Sanofi
Other prominent vendors
  • Active Biotech
  • ADC Therapeutics
  • Advantagene
  • Advaxis Pharmaceuticals
  • ANI Pharmaceuticals
  • ArQule
  • Athenex Pharmaceuticals
  • Bavarian Nordic
  • Bayer HealthCare
  • BHR Pharma
  • BMS
  • Boehringer Ingelheim
  • Camurus
  • Cleveland BioLabs
  • CureVac
  • Dendreon
  • Dextech Medical
  • Eisai
  • Endo Pharmaceuticals
  • Ferring Pharmaceutical
  • Foresee Pharmaceuticals
  • GlaxoSmithKline
  • GTx
  • Innocrin Pharmaceutical
  • Inspyr Therapeutics
  • Io Therapeutics
  • Lidds AB
  • Merck Group
  • Myovant Sciences
  • Northwest Biotherapeutics
  • Novartis
  • Nymox Pharmaceuticals
  • OncoGenex
  • Oncolytics Biotech
  • Orion
  • Pharmamar
  • Progenics Pharmaceuticals
  • Sotio
  • Spectrum Pharmaceuticals
  • Synta
  • Takeda Pharmaceuticals
  • Teva Pharmaceutical
  • Tokai Pharmaceuticals
Market driver
  • Physicians preference toward adopting hormonal therapies
  • For a full, detailed list, view our report
Market challenge
  • Presence of alternative treatment approaches
  • For a full, detailed list, view our report
Market trend
  • Emergence of targeted therapies and immunotherapies
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Prostate Cancer Drugs Market 2016-2020

Technavio recognizes the following companies as the key players in the global prostate cancer drugs market: AbbVie, Astellas Pharma, AstraZeneca, Johnson & Johnson, and Sanofi.

Other Prominent Vendors in the market are: Active Biotech, ADC Therapeutics, Advantagene, Advaxis Pharmaceuticals, ANI Pharmaceuticals, ArQule, Athenex Pharmaceuticals, Bavarian Nordic, Bayer HealthCare, BHR Pharma, BMS, Boehringer Ingelheim, Camurus, Cleveland BioLabs, CureVac, Dendreon, Dextech Medical, Eisai, Endo Pharmaceuticals, Ferring Pharmaceutical, Foresee Pharmaceuticals, GlaxoSmithKline, GTx, Innocrin Pharmaceutical, Inspyr Therapeutics, Io Therapeutics, Lidds AB, Merck Group, Myovant Sciences, Northwest Biotherapeutics, Novartis, Nymox Pharmaceuticals, OncoGenex, Oncolytics Biotech, Orion, Pharmamar, Progenics Pharmaceuticals, Sotio, Spectrum Pharmaceuticals, Synta, Takeda Pharmaceuticals, Teva Pharmaceutical, and Tokai Pharmaceuticals.

Commenting on the report, an analyst from Technavio’s team said: “The market has been witnessing a growing popularity for targeted therapies and immunotherapies, owing to their specific mechanism of action. Immunotherapies such as vaccines, and immune checkpoint inhibitors are gaining traction in the market driven by their limited side-effects, and high efficacy.”

According to the report, prostate cancer is characterized by an abnormal growth of testosterone (a hormone in the male reproductive system). Therefore, researchers have developed hormone therapies, which act by reducing the amount of testosterone in the body and stops the growth of cancer cells for several years. This development of hormone therapies and subsequent establishment of their clinical profiles have led to increased adoption among physicians.

Further, the report states that in emerging markets, the increasing costs coupled with lack of healthcare infrastructure has hindered the adoption rates of prostate cancer drugs. Most of the patients are unable to invest in these high-cost treatment options and are likely to discontinue these treatment options during the forecast period.

Companies Mentioned

AbbVie, Astellas Pharma, AstraZeneca, Johnson & Johnson, Sanofi, Active Biotech, ADC Therapeutics, Advantagene, Advaxis Pharmaceuticals, ANI Pharmaceuticals, ArQule, Athenex Pharmaceuticals, Bavarian Nordic, Bayer HealthCare, BHR Pharma, BMS, Boehringer Ingelheim, Camurus, Cleveland BioLabs, CureVac, Dendreon, Dextech Medical, Eisai, Endo Pharmaceuticals, Ferring Pharmaceutical, Foresee Pharmaceuticals, GlaxoSmithKline, GTx, Innocrin Pharmaceutical, Inspyr Therapeutics, Io Therapeutics, Lidds AB, Merck Group, Myovant Sciences, Northwest Biotherapeutics, Novartis, Nymox Pharmaceuticals, OncoGenex, Oncolytics Biotech, Orion, Pharmamar, Progenics Pharmaceuticals, Sotio, Spectrum Pharmaceuticals, Synta, Takeda Pharmaceuticals, Teva Pharmaceutical, Tokai Pharmaceuticals.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Key customer segments of global prostate cancer drugs market
  • Disease overview
    • Understanding disease
      • Table Snapshot of prostate cancer
    • Types of prostate cancer
      • Table Types of prostate cancer
    • Diagnosis
      • Table Main diagnostic procedures to determine presence of prostate cancer
    • Key buying criteria
      • Table Key buying criteria for prostate cancer drugs
      • Table Factors affecting the adoption rates of prostate cancer drugs 2015 and 2020
  • Pipeline analysis
    • Table Pipeline analysis of key vendors in global prostate cancer drugs market
    • Table Percentage share of drug candidates by stage of development
    • Table Phase III pipeline portfolio: Global prostate cancer drugs market
    • Table Phase II pipeline portfolio: Global prostate cancer drugs market
    • Table Phase I pipeline portfolio: Global prostate cancer drugs market
  • Market landscape
    • Global prostate cancer therapeutics market
      • Table Global prostate cancer therapeutics market snapshot
      • Table Analysis of global prostate cancer therapeutics market
      • Table Pipeline of global prostate cancer drugs
      • Table Global prostate cancer drugs market 2015-2020 ($ billions)
      • Table Opportunity analysis of global prostate cancer drugs market
      • Table Opportunity analysis in developed and emerging markets
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by therapy
    • Table Segmentation of global prostate cancer drugs market by therapy 2015
    • Table Life cycle analysis of key segments in global prostate cancer drugs market
    • Hormonal therapy
    • Chemotherapy
    • Immunotherapy
    • Targeted therapy
  • Geographical segmentation
    • Global prostate cancer drugs market by geographical segmentation 2015-2020
      • Table Analysis of prostate cancer drugs market by geography
      • Table Segmentation of prostate cancer drugs market based on geography 2015 and 2020
      • Table Prostate cancer drugs market revenue by geography 2015-2020 ($ billions)
    • Prostate cancer drugs market in Americas
      • Table Prostate cancer drugs market size and forecast in Americas 2015-2020 ($ billions)
      • Table Key trends across various countries in Americas
    • Prostate cancer drugs market in EMEA
      • Table Incidence of prostate cancer in key countries of EMEA 2012
      • Table Prostate cancer drugs market size and forecast in EMEA 2015-2020 ($ billions)
      • Table Trends in prostate cancer therapeutics market in EMEA
    • Prostate cancer drugs market in APAC
      • Table Prostate cancer drugs market in APAC 2015-2020 ($ billions)
      • Table Key drivers and challenges in APAC
  • Market drivers
    • Physicians preference toward adopting hormonal therapies
      • Table Performance of hormone therapies in 2015
    • Development of drugs with novel mechanism of action
      • Table Key drugs with novel mechanism of action
    • Availability of large patient pool
      • Table Potential older population with prostate cancer (65 years and above)
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Presence of alternative treatment approaches
      • Table Alternative therapies
    • High cost of drugs
      • Table Costs of key prostate cancer drugs ($ thousands)
    • Adverse side-effects of drugs
      • Table Some of the side-effects of drugs
      • Table Force field analysis of drivers and challenges in global prostate cancer drugs market
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Table Trend analysis in global prostate cancer drugs market
    • Table Key highlights of targeted therapies and immunotherapies
    • Table New advancements in diagnosis of prostate cancer
    • Table Key late stage pipeline candidates
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global prostate cancer drugs market 2015
      • Table Market share analysis 2015
      • Table Performance/initiatives of existing and upcoming vendors in global prostate cancer drugs market
      • Table Competitive analysis in global prostate cancer therapeutics market
      • Table Market penetration of various prostate cancer drug manufacturers worldwide 2015
      • Table Regional analysis of vendors in global prostate cancer drugs market
  • Key vendor analysis
    • Johnson & Johnson
      • Table Johnson & Johnson: Key highlights
      • Table Johnson & Johnson: Strength assessment
      • Table Johnson & Johnson: Strategy assessment
      • Table Johnson & Johnson: Opportunity assessment
      • Table Johnson & Johnson: YoY revenue comparison of Zytiga (Global) 2013-2015 ($ billions)
    • Astellas Pharma
      • Table Astellas Pharma: Key highlights
      • Table Astellas Pharma: Strength assessment
      • Table Astellas Pharma: Strategy assessment
      • Table Astellas Pharma: Opportunity assessment
      • Table Astellas Pharma: YoY revenue comparison of Xtandi 2014-2015 ($ billions)
    • AstraZeneca
      • Table AstraZeneca: Key highlights
      • Table AstraZeneca: Strength assessment
      • Table AstraZeneca: Strategy assessment
      • Table AstraZeneca: Opportunity assessment
      • Table AstraZeneca: YoY revenue and growth rate of Zoladex 2013-2015 ($ millions)
      • Table AstraZeneca: Geographic segmentation of Zoladex 2015
      • Table AstraZeneca: YoY revenue and growth rate of Casodex 2013-2015 ($ millions)
      • Table AstraZeneca: Geographic segmentation of Zoladex 2015
    • Sanofi
      • Table Sanofi: Key highlights
      • Table Sanofi: Strength assessment
      • Table Sanofi: Strategy assessment
      • Table Sanofi: Opportunity assessment
      • Table Sanofi: YoY revenue and growth rate of Jevtana 2013-2015 ($ millions)
      • Table Sanofi: YoY revenue and growth rate of Taxotere 2013-2015 ($ millions)
    • AbbVie
      • Table AbbVie: Key highlights
      • Table AbbVie: Strength assessment
      • Table AbbVie: Strategy assessment
      • Table AbbVie: Opportunity assessment
      • Table AbbVie: YoY revenue and growth rate of Lupron 2013-2015 ($ millions)
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report